We investigated the impact of ABO and Rhesus (Rh) blood group matching on the outcome of hematopoietic stem cell transplantation (HSCT) of 154 patients matched at 10/10 HLA loci with unrelated donors. ABO and Rh, as potential risk factors, were modeled with the clinical outcome--acute and chronic graft-versus-host disease (aGVHD, cGVHD), relapse, treatment-related mortality (TRM), and overall survival (OS)--by simple, multiple, and competing risk analyses. We found that minor ABO-mismatches represent a significant risk factor for aGVHD (II-IV) with an estimated risk increase of almost 3-fold (hazard ratio [HR]=2.92, 95% confidence interval [CI]: 1.43-5.95, P=.003), and even 4-fold for aGVHD (III-IV) (HR=4.24, 95% CI: 1.70-10.56, P=.002), but not for other transplant endpoints. No significant association of the Rh matching status with any of the HSCT endpoints was seen. These results suggest that ABO minor mismatches may play a role in aGvHD pathophysiology, possibly by providing the setting for T cell activation and antibody mediated damage. To decrease the risk of aGVHD, ABO matching should be considered in HSCT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbmt.2009.07.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Transfusion management and immuno-hematological follow-up after allogeneic hematopoietic cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Bull Cancer
February 2024
EFS site Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
Article Synopsis
- The French health authorities established guidelines for "good transfusion practices," but there is limited guidance for managing transfusions in patients who have undergone allogeneic hematopoietic stem transplantation (allo-HCT).
- A workshop aimed to standardize transfusion practices for this patient group where recommendations are lacking.
- Key recommendations include conducting extended blood cell phenotyping before transplantation, monitoring antibody levels, and assessing chimerism at specific intervals post-transplant to adjust transfusion strategies as needed.
ABO incompatibility does not affect transfusion requirements or clinical outcomes of unrelated cord blood transplantation after myeloablative conditioning for haematological malignancies.
Blood Transfus
March 2022
Department of Blood Transfusion, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Background: The effects of ABO incompatibility on cord blood transplantation (CBT) have not been confirmed. We retrospectively investigated the effect of ABO incompatibility on the clinical outcomes and changes of isoagglutinin titres of 261 consecutive patients who underwent CBT in a single centre.
Material And Methods: We studied patients with haematological malignancies undergoing unrelated CBT following myeloablative conditioning.
Impact of ABO blood group incompatibility on the outcomes of allogeneic hematopoietic stem cell transplantation.
Transfus Apher Sci
February 2020
Hacettepe University, Faculty of Medicine, Department of Hematology, Turkey.
Background And Aim: ABO and Rh compatibility are not required between the donor and recipient for allogeneic hematopoietic stem cell transplantation (alloHSCT). Although ABO incompatibility is not considered a contraindication in alloHSCT, its clinical outcomes are still doubtful. In this study, we analyzed the neutrophil and platelet recovery, graft versus host disease (GVHD), relapse rate, mortality rate, non-relapse mortality and survival in patients who underwent alloHSCT.
View Article and Find Full Text PDFPassenger lymphocyte syndrome: a forgotten cause of postliver transplant jaundice and anemia.
Exp Clin Transplant
April 2015
Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
A 48-year-old man with cirrhosis secondary to nonalcoholic steatohepatitis and chronic hepatitis C infection underwent a successful orthotopic liver transplant from a B+ donor without intraoperative complications. His postoperative course was complicated by hemolytic anemia, and he was ultimately diagnosed as having passenger lymphocyte syndrome. Passenger lymphocyte syndrome is a complication of both solid-organ and stem cell transplants.
View Article and Find Full Text PDFProphylactic red blood cell exchange for ABO-mismatched hematopoietic progenitor cell transplants.
Transfusion
July 2014
Research Service and Division of Nephrology-Hypertension, Veterans Affairs San Diego Healthcare System, Veterans Medical Research Foundation, San Diego, California; Department of Medicine, Pathology and Moore's Cancer Center, University of California at San Diego, La Jolla, California.
Background: To enhance donor availability, almost half of hematopoietic progenitor cell transplants (HPCTs) cross ABO blood type boundaries. ABO-incompatible HPCTs are well tolerated; however, there is an increased risk of delayed hemolysis in patients with minor and bidirectional ABO mismatches. Delayed hemolysis generally occurs 1 to 2 weeks after HPCT and is related to production of alloantibodies directed against recipient ABO red blood cell (RBC) antigens by passenger donor lymphocytes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!